Home >> Top News >> Binding Site offers disease state sera

Binding Site offers disease state sera

Print Friendly, PDF & Email

Nov. 2, 2017—Binding Site’s Immunologicals Group offers a comprehensive line of disease state sera in its portfolio of products available to in vitro diagnostic manufacturers and clinical/life science research facilities. The availability of these essential but frequently overlooked constituent products aims to benefit the needs of many allied health professionals, as both their sourcing and availability have been historically problematic.

Following all current regulatory and quality standards guidelines, the Immunologicals Group is able to provide materials from a variety of disease state conditions, including antinuclear antibodies, antineutrophil cytoplasmic antibodies, antiphospholipid antibodies, extractable nuclear antigens, infectious/contagious diseases, inflammation markers, and autoantibodies, focused on a variety of human organs and tissues. Materials are available in bulk formats with volumes ranging in excess of liters for use in the manufacturing of calibration and/or quality control materials. Smaller volumes may be available on request. The company can offer comprehensive data on analyte positive and negative data, along with a comprehensive certificate of analysis.

More top news


Check Also

IgG subclass antibodies

June 2018—Binding Site’s Immunologicals Group announced the availability of affinity-purified, unconjugated, anti-human antibodies to the IgG subclasses, including IgG1, IgG2, IgG3, and IgG4, for IVD research use in solid phase enzyme immunoassay based test methods, especially ELISAs, and other potential testing applications.